Between 2021 and 2031, the need for antibiotics API will increase steadily. When treating infections, it is frequently the initial option. A recent report by Future Market Insights (FMI) predicts that the market for antimicrobial APIs would surpass US$ 8.1 Billion in 2021. Medical treatments are supposed to be lot safer because to antibiotics.
Any type of surgery or long-term illness makes the patient more vulnerable to bacterial infection. The market for antibiotics API is anticipated to be driven by the rising prevalence of infections such tuberculosis, pneumonia, blood poisoning, gonorrhoea, and foodborne illnesses.
According to the World Health Organization (WHO), antibiotics can be used to treat bacterial pneumonia. Pneumonia was a contributing factor in about 15% of child fatalities in 2017. According to UNICEF data from 2018, there are over 1,400 cases of pneumonia per 100,000 children worldwide, with South Asia and West and Central Africa having the highest incidences (2,500 cases per 100,000 children each) (1,620 cases per 100,000 children)
The market for antibiotic APIs is thought to be negatively impacted by the COVID-19 pandemic. To address the issue, some of the top pharmaceutical corporations, research institutions, and biotech firms have been selected. Because of this, they are now concentrating on developing coronavirus vaccines rather than other medications. Various APIs are in short supply, and hospital beds are limited.
Request a report sample to gain comprehensive insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-13025
In terms of API, penicillin antibiotics segment dominated the antibiotics API market with a market share of 51.1% in 2021 owing to the increasing demand and adoption of penicillin as a first-line antibiotic therapy to treat several bacterial infections. Pharmaceutical companies are expected to rule the end user segment. They are expected to hold over 77% of the market and remain dominant through the forecast period.
Key Takeaways from Antibiotics API Market Study
- The global antibiotics API market is estimated to be US$ 8.01 Bn in 2020, with the market expected to exhibit a CAGR of 3.1% during the forecast period (2020-2030)
- The U.S. holds over 92.1% share of the North America market, but Canada is projected to expand faster CAGR
- The U.K. market will showcase steady y-o-y growth at 2.1% in 2021
- The demand from Germany and France will rise at a positive rate through the forecast period
- Within East Asia China will emerge as a key market, while Japan and South Korea will continue exhibiting steady demand
“Increasing prevalence of bacterial diseases, extreme use of antibiotics and rising investment in R&D are expected to boost the growth of the antibiotics API market.” says the FMI Analyst
Rising investment in R&D sector in order to develop advanced molecules is the major factor expected to boost the antibiotic API market growth.
For instance, Sandoz, the Novartis biosimilars and generics division, undergoes a joint investment, with the Austrian federal government, to enhance the long-term future of integrated antibiotics manufacturing in Europe.
Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-13025
Key players in the Antibiotics API are Entering into Strategic Alliance
The top players are focusing on increasing acquisitions at regional levels. Acquisitions empower the company with products and increase the company’s portfolio. The company acquires to possess well-established products and solutions that expects to account good revenue source for the acquirer. This also enables the company to enter new emerging markets as well as enhance the existing markets.
For instance, in August 2019, Nanjing Dorra Pharmaceutical Technology collaborated with Meitheal Pharmaceuticals, the fully integrated generic injectables company, for elevating the manufacturing capacity of the active pharmaceutical ingredients in the region of U.S. The collaboration enabled Meitheal Pharmaceuticals to invest into the Nanjing Dorra Pharmaceutical Technology.
Who is Winning?
The global antibiotics API market is set to expand its scope in the forecast period, as a result of rising prevalence of various bacterial diseases, and growing investment in R&D. The antibiotics market is highly competitive and consists of several major players. Pharmaceutical companies are more focused towards outsourcing of antibiotics API manufacturing due to the involvement of high capital investment in the establishment of Antibiotics API manufacturing units.
The key market players covered by FMI include Sandoz International GmbH, Centrient Pharmaceuticals, CordenPharma International, ACS DOBFAR SPA, Nanjing Dorra Pharmaceutical Technology Co. Ltd., DAEWOONG PHARMACEUTICAL CO. LTD., Parabolic Drugs Ltd., Penam Laboratories Ltd., ASIATIC DRUGS & PHARMACEUTICALS PVT. LTD., Fresenius Kabi, The United Laboratories International Holdings Limited, Aurobindo Pharma Limited, Unimark Remedies Ltd., Savior Lifetec, Shenzhen Haibin Pharmaceutical Co., Ltd., Sterile India Pvt. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., and Kyongbo Pharm, consolidating their positions through mergers, acquisitions and new product launches.
Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-13025
About FMI
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
Report: https://www.futuremarketinsights.com/reports/antibiotics-active-pharmaceutical-ingredient-api-market
For Sales Enquiries: sales@futuremarketinsights.com
Browse latest Market Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
